InSPECt™ MS – Global HCP Profiling and Quantification by Native Digestion and LC-MS Analysis

Why It Matters

Accurate, protein‑level HCP quantification enables tighter control of biopharmaceutical safety and streamlines regulatory submissions, offering a clear advantage over traditional ELISA that only provides aggregate signals.

Key Takeaways

• inSPECt™ quantifies HCPs using native digestion and spiked‑in standards.
• Linear response observed from 10 to 500 ppm with <18% CV.
• Detected 51 HCPs in NIST mAb; 29 above 5 ppm LOD.
• Spike‑recovery tests show ≤10% error for problematic HCPs.

Pulse Analysis

Host‑cell protein impurities have long challenged biologics developers because they can trigger immunogenicity or degrade product efficacy. Conventional ELISA assays, while sensitive, mask the identity of individual HCPs, forcing manufacturers to rely on indirect risk assessments. Recent advances in data‑independent LC‑MS workflows have begun to fill this gap, yet the dynamic range of therapeutic proteins still overwhelms low‑abundance contaminants. Native digestion—where the drug substance remains largely intact while HCPs are preferentially cleaved—offers a clever solution, enriching the very species that need measurement without extensive sample manipulation.

The inSPECt™ MS approach builds on this concept by spiking a calibrated protein mixture (Cygnus Protein Standard) into the sample matrix and using high‑resolution Orbitrap detection coupled with the CHIMERYS algorithm. Calibration curves across 10‑500 ppm displayed R² values above 0.95 and median response factors that reliably translate signal intensity into parts‑per‑million concentrations. In practice, the method identified 51 distinct HCPs in the NIST monoclonal‑antibody reference, matching published DIA/DDA datasets and confirming its quantitative fidelity. Spike‑in recovery tests for three historically troublesome HCPs yielded errors under 10 % and consistent precision, underscoring the platform’s suitability for both routine lot release and deep‑process development.

For the biopharma industry, this level of granularity translates into actionable data that can be fed directly into risk‑based control strategies and regulatory filings. By delivering absolute concentrations rather than relative ELISA signals, manufacturers can set scientifically justified specifications, reduce unnecessary purification steps, and potentially accelerate time‑to‑market. As more companies adopt LC‑MS‑based HCP profiling, tools like inSPECt™ are poised to become standard components of the analytical toolbox, reinforcing product safety while supporting cost‑effective manufacturing.